NASDAQ: MBRXMoleculin Biotech Inc Stock
$4.52+0.24 (+5.61%)
Updated Apr 18, 2024
MBRX Price
$4.52
Fair Value Price
$11.63
Market Cap
$10.08M
52 Week Low
$4.28
52 Week High
$15.75
P/E
-0.3x
P/B
0.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$29.77M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.47
Operating Cash Flow
-$24M
Beta
0.87
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MBRX Overview
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MBRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MBRX ($4.52) is undervalued by 61.1% relative to our estimate of its Fair Value price of $11.63 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MBRX ($4.52) is significantly undervalued by 61.1% relative to our estimate of its Fair Value price of $11.63 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MBRX due diligence checks available for Premium users.
Be the first to know about important MBRX news, forecast changes, insider trades & much more!
MBRX News
Valuation
MBRX fair value
Fair Value of MBRX stock based on Discounted Cash Flow (DCF)
Price
$4.52
Fair Value
$11.63
Undervalued by
61.13%
MBRX ($4.52) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MBRX ($4.52) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MBRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.3x
Industry
15.68x
Market
41.33x
MBRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.39x
Industry
5.76x
MBRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MBRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.3M
Profit Margin
0%
MBRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$38.2M
Liabilities
$12.1M
Debt to equity
0.47
MBRX's short-term assets ($26.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MBRX's short-term assets ($26.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MBRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MBRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.4M
Investing
-$81.0k
Financing
$4.5M
MBRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MBRX vs Biotech Stocks
Moleculin Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.